来宝网 2012/11/15点击1937次
康涅狄格州GUILFORD--(美国商业资讯)--Defibtech, LLC是自动体外除颤仪(AED)及其他复苏设备的设计商和制造商，该公司今天宣布已与总部设在东京的医疗器械公司日本光电签署一项协议，由日本光电收购该公司。
技术和功能的显著扩展
两家公司的整合将在全球AED市场上创造一支加强力量。Defibtech公司与日本光电已在全球投放了超过36万台AED，并希望该数字有大幅增加。Defibtech公司规划在AED市场上增添该公司作为一家创新和不断成长的公司的商誉。此外，Defibtech公司打算针对若干其他复苏市场加速其产品开发。
Defibtech公司首席执行官Glenn W. Laub博士说："Defibtech公司将不仅继续扩展其AED产品线，同时还计划开发和营销其他复苏解决方案。十年来，我们在世界各地部署了超过16万台AED，是复苏市场上一支稳步壮大的力量。我们希望继续这种增长。"Defibtech公司的 AED的标志是优良的制造工艺和可用性、创新的设计和可承受的定价，其卓越性获得安全性专家、工业设计组织和忠诚客户的认可。Laub博士表示："我们的新款复苏解决方案将拥有同样高水平的价值和质量。"
Defibtech公司将作为日本光电的美国分公司、总部设在特拉华州的Resuscitation Solution Inc.的全资子公司继续独立运营。Defibtech公司总裁Gintaras Vaisnys说："这是Defibtech公司与日本光电优势互补的大好机会。日本光电是医疗器械领域的一支领先力量，它的全球性优势将提升Defibtech公司的创新商业模式。我们很高兴看到这一关系可能带来若干新产品发的开发和市场机遇，这将帮助Defibtech公司在今后数年迅猛增长。"Defibtech公司的产品将继续使用Defibtech公司美誉度很高的商品名，并由Defibtech公司的员工进行设计、制造和支持。
美国市场的业务拓展
拓展美国市场的业务是日本光电的战略目标。目前，日本光电在美国的运营主要通过其神经科和患者监护业务。通过收购Defibtech公司，日本光电将进军世界最大的美国复苏市场。
美国也是引领复苏科学研究的中心，其知识成果有力左右着该领域的世界潮流。收购Defibtech公司后，日本光电就在美国拥有了复苏解决方案的开发基地， 能够使这一整合组织在早期识别市场趋势、加强与领先研发机构的合作、开发适合全球销售的创新复苏技术。
关于 Defibtech
Defibtech, LLC坚定追求一个目标：以可承受的价格在全球营销最佳AED。Defibtech公司设计、制造除颤仪，包括LifelineTM 和 ReviveRTM 家族AED。Defibtech公司的产品通过其在美国和全球的经销伙伴网络发售。Defibtech公司总部位于康涅狄格州Guilford。Defibtech公司的所有AED均在美国一流的ISO 13485:2003认证工厂制造。有关Defibtech公司及其产品的进一步信息，请访问www.defibtech.com 或拨打+1-203-453-4507。
关于日本光电
日本光电是日本领先的医疗电子设备制造商和提供商。日本光电年销售额达15亿美元，是世界100大医疗器械公司之一。日本光电是东京证券交易所上市的公众持股公司。有关日本光电的进一步信息，请访问www.nihonkohden.com。
免责声明：本公告之原文版本乃官方授权版本。译文仅供方便了解之用，烦请参照原文，原文版本乃唯一具法律效力之版本。
联系方式:
Defibtech, LLC
Ray Valek, 708-352-8695
ray@defibtech.com
Defibtech Signs Agreement to be Acquired by Nihon Kohden Corporation
Defibtech, LLC, a designer and manufacturer of automated external defibrillators (AEDs) and other resuscitation equipment, announced today that it has signed an agreement to be acquired by the Nihon Kohden Corporation, a Tokyo-based medical device company.
A significant expansion of technologies and capabilities
The integration of the two companies will create a strengthened force in the global AED market. Defibtech and Nihon Kohden have placed more than 360,000 AEDs throughout the world and expect that number to increase significantly. Defibtech plans to add to its reputation as an innovative and growing company in the AED market. In addition, Defibtech intends to accelerate its development of products targeting a number of other resuscitation markets.
“Defibtech will not only continue expanding its AED product lineup, but also plans to develop and market other resuscitation solutions,” said Defibtech CEO Dr. Glenn W. Laub. “Over the past decade, having deployed more than 160,000 AEDs worldwide, we are a steadily growing force in the resuscitation market. We want to continue that growth.” Recognized as outstanding by safety experts, industrial design organizations and loyal customers, Defibtech AEDs are marked by superior engineering and usability, innovative design, and affordable pricing. “Our new resuscitation solutions will have the same high level of value and quality,” Dr. Laub stated.
Defibtech will continue to operate independently as a wholly owned subsidiary of Delaware-based Resuscitation Solution Inc., a U.S. subsidiary of Nihon Kohden, said Gintaras Vaisnys, Defibtech President. “This is a great opportunity for Defibtech and Nihon Kohden to complement their strengths,” he stated. Defibtech’s innovative business model will be further enhanced by the global strength of Nihon Kohden, a leading force in the medical device field. “We are excited about a number of new product development and market opportunities that may result from this relationship, which will help Defibtech grow aggressively in the coming years,” said Vaisnys. Defibtech’s products will continue to bear the highly respected Defibtech name and be designed, manufactured and supported by Defibtech personnel.
Expansion of business in the U.S. market
For Nihon Kohden, expanding its business in the U.S. market is a strategic goal. Currently, Nihon Kohden operates in the U.S. primarily through its neurology and patient monitoring businesses. Through the acquisition of Defibtech, Nihon Kohden will enter the U.S. resuscitation market, the largest in the world.
The U.S. is also a center of pioneering research in resuscitation science, and the resulting knowledge strongly influences worldwide trends in this field. Nihon Kohden’s acquisition of Defibtech establishes a U.S. development base for resuscitation solutions, enabling the integrated organizations to identify market trends in early stages, strengthen collaboration with leading research and development institutes, and develop innovative resuscitation technology for sale throughout the world.
About Defibtech
Defibtech, LLC, relentlessly pursues one goal: making the best AEDs in the world at affordable prices. Defibtech designs and manufactures defibrillators, which include the Lifeline™ and ReviveR™ families of AEDs. Defibtech’s products are sold through its network of distribution partners in the United States and around the world. Defibtech is headquartered in Guilford, Conn. All Defibtech AEDs are manufactured in the United States in state-of-the-art ISO 13485:2003 certified facilities. For more information about Defibtech and its products, visit www.defibtech.com or call +1-203-453-4507.
About Nihon Kohden
Nihon Kohden is Japan's leading manufacturer and provider of electronic medical equipment. With annual sales topping $1.5 billion, Nihon Kohden is one of the top 100 medical device companies in the world. Nihon Kohden is a publicly held company listed on the Tokyo Stock Exchange. For more information about Nihon Kohden, go to www.nihonkohden.com.
